This company has been acquired
Semler Scientific (SMLR) Aandelenoverzicht
Semler Scientific, Inc. biedt technologische oplossingen om de klinische effectiviteit en efficiëntie van zorgverleners in de Verenigde Staten te verbeteren. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
SMLR Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Semler Scientific, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$20.33 |
| 52 Week Hoogtepunt | US$65.98 |
| 52 Week Laag | US$14.89 |
| Bèta | 1.32 |
| 1 maand verandering | 13.39% |
| 3 maanden verandering | -9.76% |
| 1 Jaar Verandering | -68.69% |
| 3 jaar verandering | -45.31% |
| 5 jaar verandering | -77.41% |
| Verandering sinds IPO | 190.84% |
Recent nieuws en updates
SMLR: All Stock Strive Deal Will Unlock Bitcoin Treasury Upside
Analysts have reaffirmed their fair value estimate for Semler Scientific at US$86.00, highlighting adjusted assumptions around the discount rate, revenue trends and profit margin, along with a lower but still very large future P/E expectation as the key drivers behind holding the target steady. What's in the News Strive, Inc.
SMLR: Future Profits And January Meeting Will Support Bullish Thesis
Analysts have reduced their price target on Semler Scientific from US$60.00 to US$51.00, citing softer revenue growth assumptions, a higher discount rate, and a very large future P/E multiple, even as projected profit margins edge slightly higher. What's in the News Semler Scientific has scheduled a special or extraordinary shareholders meeting for January 13, 2026, giving investors a date to watch for company level decisions or approvals that require shareholder input (Key Developments).Recent updates
SMLR: All Stock Strive Deal Will Unlock Bitcoin Treasury Upside
Analysts have reaffirmed their fair value estimate for Semler Scientific at US$86.00, highlighting adjusted assumptions around the discount rate, revenue trends and profit margin, along with a lower but still very large future P/E expectation as the key drivers behind holding the target steady. What's in the News Strive, Inc.SMLR: Future Profits And January Meeting Will Support Bullish Thesis
Analysts have reduced their price target on Semler Scientific from US$60.00 to US$51.00, citing softer revenue growth assumptions, a higher discount rate, and a very large future P/E multiple, even as projected profit margins edge slightly higher. What's in the News Semler Scientific has scheduled a special or extraordinary shareholders meeting for January 13, 2026, giving investors a date to watch for company level decisions or approvals that require shareholder input (Key Developments).SMLR: All Stock Acquisition Will Unlock Bitcoin Treasury Upside
Analysts have reduced their price target on Semler Scientific to $86 from $101, citing lower revenue and margin forecasts, as well as uncertainty and opportunity created by the recent all stock acquisition agreement and legal settlement. Analyst Commentary Bullish analysts acknowledge the reduced price targets but continue to frame the all stock acquisition and legal settlement as catalysts that could unlock value for Semler Scientific over the medium term.
SMLR: Shares Will Rise As All Stock Acquisition Drives Bitcoin Treasury Consolidation
Analysts have trimmed their average price target for Semler Scientific by about $15 to roughly $83 per share, citing reduced revenue expectations following updated management guidance and the implications of the recent DOJ settlement. They continue to view the stock as an attractive opportunity in light of the pending all stock acquisition by Strive and consolidation prospects in the corporate bitcoin treasury space.SMLR: Shares Will Reflect Upside As $1.4 Billion Acquisition Advances
Analysts have lowered their fair value estimate for Semler Scientific by approximately $10. This change is due to reduced revenue growth projections and updated guidance in light of recent acquisition and settlement developments.Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Analysts have lowered their price target for Semler Scientific from $85.33 to $75.33, citing reduced revenue forecasts following cautious management guidance, weighing of recent legal settlements, and uncertainty around the company’s pivot to a bitcoin treasury strategy despite some bullish views on its potential long-term re-rating. Analyst Commentary Bullish analysts see the acquisition by Strive (ASST) as triggering potential consolidation in the corporate bitcoin treasury sector, presenting a timely opportunity despite market uncertainty around the transaction’s longer-term implications.Is Semler Scientific (NASDAQ:SMLR) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Diversification into cardiac disease markets and value-based care tools positions the company for higher recurring revenues and improved long-term margins.Semler Scientific, Inc.'s (NASDAQ:SMLR) 26% Share Price Surge Not Quite Adding Up
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have had a really impressive month, gaining 26% after a shaky period...Semler Scientific: Not The Ideal Bitcoin Treasury Company
Summary Semler Scientific's pivot to a Bitcoin treasury strategy has been successful. However, competition in the Bitcoin Treasury company space is heating up, including many well funded competitors. Declining revenues and free cash flow in its healthcare business are concerning, and Bitcoin is materially outperforming the Company year to date. Read the full article on Seeking AlphaSemler Scientific, Inc.'s (NASDAQ:SMLR) 32% Price Boost Is Out Of Tune With Revenues
Semler Scientific, Inc. ( NASDAQ:SMLR ) shareholders are no doubt pleased to see that the share price has bounced 32...Here's Why We Think Semler Scientific (NASDAQ:SMLR) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Semler Scientific's (NASDAQ:SMLR) Profits May Not Reveal Underlying Issues
The recent earnings posted by Semler Scientific, Inc. ( NASDAQ:SMLR ) were solid, but the stock didn't move as much as...Semler Scientific, Inc. (NASDAQ:SMLR) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Semler Scientific, Inc. ( NASDAQ:SMLR ) share price has dived 25% in the last...Semler Scientific, Inc. (NASDAQ:SMLR) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have retraced a considerable 26% in the last month, reversing a fair...Rendement voor aandeelhouders
| SMLR | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -0.05% | 0.03% | 2.2% |
| 1Y | -68.7% | -20.4% | 24.8% |
Rendement versus industrie: SMLR presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van -20.4 % opleverde.
Rendement versus markt: SMLR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 24.8 % opleverde.
Prijsvolatiliteit
| SMLR volatility | |
|---|---|
| SMLR Average Weekly Movement | 18.6% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van SMLR is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 19% ) van SMLR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | 79 | Doug Murphy-Chutorian | www.semlerscientific.com |
Semler Scientific, Inc. biedt technologische oplossingen om de klinische effectiviteit en efficiëntie van zorgverleners in de Verenigde Staten te verbeteren. Tot de producten van het bedrijf behoort QuantaFlo, een vier minuten durende bloeddoorstromingstest waarmee zorgverleners de bloeddoorstroming kunnen meten als onderdeel van hun onderzoek naar de vasculaire conditie van een patiënt. De producten van het bedrijf worden gebruikt door cardiologen, internisten, nefrologen, endocrinologen, podologen, huisartsen, zorgverzekeraars, geïntegreerde netwerken, onafhankelijke artsengroepen en bedrijven die samenwerken met de gezondheidszorg, zoals risicobepalende groepen en detailhandelaren.
Semler Scientific, Inc. Samenvatting
| SMLR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$310.75m |
| Inkomsten(TTM) | US$48.34m |
| Inkomsten(TTM) | US$36.96m |
Is SMLR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SMLR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$36.96m |
| Kosten van inkomsten | US$3.41m |
| Brutowinst | US$33.54m |
| Overige uitgaven | -US$14.80m |
| Inkomsten | US$48.34m |
Laatst gerapporteerde inkomsten
Sep 30, 2025
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 3.16 |
| Brutomarge | 90.76% |
| Nettowinstmarge | 130.80% |
| Schuld/Eigen Vermogen Verhouding | 25.3% |
Hoe presteerde SMLR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/01/20 12:08 |
| Aandelenkoers aan het einde van de dag | 2026/01/15 00:00 |
| Inkomsten | 2025/09/30 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Semler Scientific, Inc. wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Mark Palmer | Benchmark Company |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Brett Knoblauch | Cantor Fitzgerald & Co. |